SNC109 / Shanghai Simnova Bio - LARVOL DELTA

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM (clinicaltrials.gov) - P1 | N=50 | Enrolling by invitation | Sponsor: Shanghai Simnova Biotechnology Co.,Ltd.

CAR T-Cell Therapy • New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Shanghai Simnova Biotechnology Co.,Ltd. | Trial primary completion date: Aug 2023 ➔ May 2024

CAR T-Cell Therapy • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Xianbo Biologics’ dual CAR-T therapy obtains FDA orphan drug status [Google translation] (163.com) - "On January 23, Xianbio announced that it had received an official response from the U.S. FDA that its independently developed SNC109 injection had been granted orphan drug status for the treatment of malignant glioma. Public information shows that SNC109 injection is a dual CAR-T cell therapy carrying two CAR molecules independently developed by Xianbo Biotechnology based on the BiTE CAR-T platform."

Orphan drug • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Xianbo Biotechnology: IND application for CAR-T cell therapy was accepted by CDE [Google translation] (pharnexcloud.com) - "...CDE official website showed that the IND application for 'SNC109 Injection' of Shanghai Xianbo Biotechnology Co., Ltd...has been accepted by CDE....SNC-109 injection is a CAR-T cell specifically targeting glioblastoma. It is a dual-arm BiTE-armored dual CAR-T cell."

New trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Shanghai Simnova Biotechnology Co.,Ltd.

CAR T-Cell Therapy • New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • IL6